Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
June 17, 2019
Oslo Cancer Cluster

Nobel Prize winner joins Lytix Biopharma

The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for Oslo Cancer Cluster member Lytix BioPharma.

Nobel Prize winner joins Lytix Biopharma

The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for Oslo Cancer Cluster member Lytix BioPharma.

The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for our member Lytix BioPharma.

Oslo Cancer Cluster’s member Lytix BioPharma announced this week that the cancer researchers and married couple Dr James Allison (PhD) and Dr Padmanee Sharma (MD) will join their Scientific Advisory Board.

Dr James Allison was, together with Dr Tasuku Honjo, awarded the 2018 Nobel Prize in Medicine last December. The renowned cancer researchers received the award for their ground-breaking work in immunology. It has become the basis for different immunotherapies, an area within cancer therapy that aims to activate the patient’s immune system to fight cancer.

Dr Sharma is a distinguished oncologist, who has focused her work on understanding different resistant mechanisms in the immune system. These resistant mechanisms sometimes hinder immunotherapies from working on every cancer tumour and every cancer patient.

Lytix Biopharma is a biotech company, located in the Oslo Cancer Cluster Incubator, that develops novel cancer immunotherapies. They are making an “oncolyctic peptide” – a drug with the potential to personalize every immunotherapy to fit each patient.

  • Please visit Lytix BioPharma’s official website for more information about their product

Edwin Clumper, CEO of Lytix BioPharma, expressed how thrilled he was to welcome Dr Allison and Dr Sharma:

“We are honoured that they have offered their support to further the development of our oncolytic peptides with the aim to tackle tumour heterogeneity – an unresolved challenge in cancer treatment.”

Last updated:
June 17, 2019

Oslo Cancer Cluster

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines. We are a national non-profit member organisation with about 90 members.

Click here to read more about us!
Get in touch with us!
Visit us

Oslo Cancer Cluster
Ullernchausséen 64
0379 Oslo

Send us mail

The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for our member Lytix BioPharma.

Oslo Cancer Cluster’s member Lytix BioPharma announced this week that the cancer researchers and married couple Dr James Allison (PhD) and Dr Padmanee Sharma (MD) will join their Scientific Advisory Board.

Dr James Allison was, together with Dr Tasuku Honjo, awarded the 2018 Nobel Prize in Medicine last December. The renowned cancer researchers received the award for their ground-breaking work in immunology. It has become the basis for different immunotherapies, an area within cancer therapy that aims to activate the patient’s immune system to fight cancer.

Dr Sharma is a distinguished oncologist, who has focused her work on understanding different resistant mechanisms in the immune system. These resistant mechanisms sometimes hinder immunotherapies from working on every cancer tumour and every cancer patient.

Lytix Biopharma is a biotech company, located in the Oslo Cancer Cluster Incubator, that develops novel cancer immunotherapies. They are making an “oncolyctic peptide” – a drug with the potential to personalize every immunotherapy to fit each patient.

  • Please visit Lytix BioPharma’s official website for more information about their product

Edwin Clumper, CEO of Lytix BioPharma, expressed how thrilled he was to welcome Dr Allison and Dr Sharma:

“We are honoured that they have offered their support to further the development of our oncolytic peptides with the aim to tackle tumour heterogeneity – an unresolved challenge in cancer treatment.”

Last updated:
June 17, 2019

Oslo Cancer Cluster

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines. We are a national non-profit member organisation with about 90 members.

Click here to read more about us!
Get in touch with us!
Visit us

Oslo Cancer Cluster
Ullernchausséen 64
0379 Oslo

Send us mail